is there a link between glp-1 drugs and blood clots Ozempic & Clots: New Study Shows Lower Risk with GLP-1 Agonists in Cardiovascular Diseases:

These statements have not been evaluated by the Food and Drug Administration

A key feature of the consensus is its endorsement of shared decision-making, taking into account patient goals, preferences, access, and affordability

Learn how SmithRx helps optimize pharmacy spend while supporting member health.

Gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain are among the most frequently reported side effects, especially at the start of treatment

or oral administration

The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022